{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:00:57Z","timestamp":1793815257333,"version":"4.6.1"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Preferred Reporting Items for Systematic Reviews and Meta\u2010Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab's effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>\n                      According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid\u2010beta plaques (difference,.45; 95% confidence interval,.67 to.23;\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.001). Participants who received lecanemab saw a greater frequency of amyloid\u2010related imaging abnormalities (ARIA)\u2010H (17.3% vs. 9.0%) and ARIA\u2010E (12.6% vs. 1.7%), which is a significant adverse outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (A\u03b2 and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/brb3.3592","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T01:43:41Z","timestamp":1718243021000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Use of lecanemab for the treatment of Alzheimer's disease: A systematic review"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-6077","authenticated-orcid":false,"given":"Md Fahad","family":"Hossain","sequence":"first","affiliation":[{"name":"Ministry of Health and Family Welfare  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashma Ul","family":"Husna","sequence":"additional","affiliation":[{"name":"Mercy Health St. Elizabeth Youngstown Hospital  Youngstown Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Kharel","sequence":"additional","affiliation":[{"name":"Department of Medicine Kathmandu Medical College Kathmandu Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010019\u201004564\u20105"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010180766"},{"key":"e_1_2_9_4_1","unstructured":"Eisai and Biogen. (2021).Announce positive topline results of the final analysis for phase III clinical study (clarity AD\/study 301) of lecanemab (BAN2401) in patients with early Alzheimer's disease.Eisai Co Ltd. and Biogen Inc."},{"key":"e_1_2_9_5_1","volume-title":"FDA grants accelerated approval for Alzheimer's disease treatment","author":"Food and Drug Administration (FDA)","year":"2023"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1132814"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2011.01.002"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2101"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004710"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010220841"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.41"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2013.12.003"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3505"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0166\u20102236(00)01749\u20105"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010016\u20100181\u20102"},{"key":"e_1_2_9_16_1","article-title":"Alzheimer's disease : FDA approves lecanemab amid cost and safety concerns","author":"Mahase E.","year":"2023","journal-title":"BMJ"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000547"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006338"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010016\u20100384\u20104"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_21_1","first-page":"00","article-title":"Aducanumab, lecanemab for early AD: The clinical trials that led to FDA approval","volume":"00","author":"Rodriquez M. T.","year":"2023","journal-title":"Medical Bag"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1229"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010019\u20100205\u20101"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101823"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002609"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.07.009"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259\u2010023\u201006177\u20105"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.12.064"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.3592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T02:01:24Z","timestamp":1719453684000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.3592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1002\/brb3.3592"],"URL":"https:\/\/doi.org\/10.1002\/brb3.3592","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/BRB3.3592\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3592\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3592\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/BRB3.3592\/v1\/review1","asserted-by":"object"}]},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"2023-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3592"}}